WuXi AppTec wins CRDMO award as WuXi AppTec stock trades at EUR 22.17
Published on 10/21/2026 at 09:54 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSCRDMO growth and reporting date
- Frost & Sullivan recognized WuXi AppTec on October 20, 2026, for CRDMO leadership.
- WuXi AppTec raised its fiscal year 2026 revenue guidance to RMB 58.5 billion to RMB 60.5 billion.
- WuXi AppTec stock trades at EUR 22.17 at 9:43 a.m. CEST at Lang & Schwarz on October 21, 2026.
WuXi AppTec (ISIN CNE100003F19) received the 2026 Global Company of the Year recognition for contract research, development and manufacturing on October 20, 2026. PR Newswire reported that Frost & Sullivan gave the award after assessing strategy effectiveness and execution.
The award adds a current operating signal to a company already showing rapid growth. WuXi AppTec said its CRDMO platform supports drug research, development and manufacturing across Asia, Europe and North America, while the award release said the company operates across more than 30 countries.
Three milestones shape the picture
The recent chronology runs from first-quarter results on April 27, 2026, to higher full-year guidance on October 7, 2026, and the industry recognition on October 20, 2026. For the first quarter, Simply Wall St reported revenue of CNY 12.4 billion and net income of CNY 4.65 billion. On October 7, the same source reported that WuXi AppTec lifted fiscal year 2026 total revenue guidance to RMB 58.5 billion to RMB 60.5 billion from RMB 51.3 billion to RMB 53.0 billion.
What does the guidance mean?
The guidance range is the clearest quantified measure of management's growth ambition. Its lower end is RMB 7.2 billion above the previous lower end, while its upper end is RMB 7.5 billion higher. The comparison matters because it links the award's strategic message to a concrete financial target.
When are the next results due?
WuXi AppTec is scheduled to publish third-quarter 2026 results on October 26, 2026, according to Moomoo News. The preview puts expected third-quarter revenue at CNY 15.29 billion, up 26.84 percent from the prior-year quarter, and estimated earnings per share at CNY 2.28, up 86.90 percent.
Stock price and investor context
The recognition arrives before the next reporting date, giving investors two measurable reference points: the expanded revenue range and the coming quarterly release. The award itself is qualitative, while the guidance and forecast provide the numerical tests for the CRDMO growth strategy.
WuXi AppTec was trading at EUR 22.17 at Lang & Schwarz on October 21, 2026 at 9:43 a.m. CEST. The further course of trading is shown by the continuously updated real-time quote of WuXi AppTec stock.
WuXi AppTec stock facts
- Company: WuXi AppTec Co., Ltd.
- ISIN: CNE100003F19
- Ticker: WX8
- Price Lang & Schwarz (as of October 21, 2026, 9:43 a.m. CEST): EUR 22.17
- Sector / Industry: Healthcare / Medical Diagnostics and Research
- Index membership: Shanghai Composite
Market context: Market report Shanghai Composite.
